arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Quince Therapeutics, Inc.

QNCX

$30.43 ▲ +0.75 (+2.51%) at close

9 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Good

Bullish

auto_awesome

Analytical Summary

Quince Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $1.5B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC 169.1% ↗

FCF / Share $-0.83 ↘

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity 0.00

info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-83.98M

↓ -47.8% —

FCF / Share Free cash flow per share

$-0.83

↓ -12.2% —

Long-Term Debt Long-term obligations

$0.00

↓ -100.0% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)
Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns

100

Financial Health ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
EPS Growth YoY (%)	-28.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-56.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	45.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	49.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	-47.8% Weak ↓ Weak Declining Year-over-year change in net income	-81.1% Weak ↓ Weak Declining Year-over-year change in net income	39.2% Excellent ↑ Excellent Improving Year-over-year change in net income	42.6% Excellent ↑ Excellent Improving Year-over-year change in net income	-17.0% Weak ↑ Weak Improving Year-over-year change in net income	-107.8% Weak Weak Year-over-year change in net income	-196.4% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-12.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	-50.0% Weak ↓ Weak Declining Year-over-year change in free cash flow	62.4% Excellent Excellent Year-over-year change in free cash flow	37.9% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Effective Tax Rate (%) (%)	-4.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.6% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.5% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—
FCF / Net Income (x)	0.50x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.57x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.59x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.70x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Return on Invested Capital (%)	169.1% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-129.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-34.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-51.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-76.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-36.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-26.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	29.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-62.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-50.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-20.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-50.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-67.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-41.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-31.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-16.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	235.1% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1468%)	-188.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1357%)	-36.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-346%)	-51.4% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-442%)	-75.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-606%)	-44.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-397%)	-32.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-313%)	38.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+155%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Debt to Equity (x)	0.00x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.48x Good ↑ Good Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-21%)	0.16x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-74%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—	—	—	—
Interest Coverage (x)	-248.15x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—	-12.66x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-5.81M	$8.11M	$13.43M	$0.00	—	—	—	$-24.87M	—
Debt / EBITDA (x)	0.00x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.25x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.39x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Basic EPS, GAAP (USD)	$-1.68	$-1.31	$-0.84	$-1.54	$-3.03	—	—	—	—
Free Cash Flow per Share (USD)	$-0.83	$-0.74	$-0.50	$-1.32	$-2.12	—	—	—	—
Book Value per Share (USD)	$-0.64	$0.69	$1.98	$2.78	$3.94	$5.83	$4.30	$-9.56	—
Tangible Book Value per Share (USD)	$-1.86	$-0.68	$0.09	$2.62	$3.94	$5.83	$4.30	$-9.56	—
Basic Weighted Avg Shares (shares)	50.10M	43.26M	37.24M	33.50M	29.72M	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$-20.33M	$36.76M	$67.87M	$90.68M	$97.45M	$120.87M	$97.16M	$71.13M	—
LT Debt (USD)	$0.00	$14.32M	$13.43M	$0.00	—	—	—	—	—
Total Equity (USD)	$-35.71M	$30.15M	$85.08M	$100.59M	$118.59M	$172.26M	$115.48M	$-32.63M	$-20.28M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Depreciation Expense (USD)	$100.00K	$200.00K	$300.00K	$200.00K	$344.00K	$332.00K	$188.00K	$51.00K	—
Net Income, GAAP (USD)	$-83.98M	$-56.83M	$-31.39M	$-51.66M	$-89.94M	$-76.85M	$-36.98M	$-12.48M	—
Operating Cash Flow (USD)	$-41.42M	$-31.90M	$-18.29M	$-44.04M	$-62.93M	$-50.82M	$-33.28M	$-11.70M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters

Quince Therapeutics, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare QNCX with peers